Recent Updates
Recently added Catalysts
MGNX Negative Sentiment Score: 25/100

MACROGENICS ALERT: Bragar Eagel & Squire, P.C. is Investigating MacroGenics, Inc. on Behalf of MacroGenics Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is conducting an investigation into MacroGenics, Inc. on behalf of its stockholders. This investigation is related to potential claims of violations of federal securities laws and other unlawful business practices. Recently, MacroGenics disclosed that five patients died during its TAMARACK clinical trial, which led to a drastic drop in its stock price, falling over 70%. The law firm is encouraging investors who believe they have suffered losses to come forward and participate in the action.

Market Sentiment Analysis

CONCERNS & RISKS

  • MacroGenics admitted that five patients died during its TAMARACK study.
  • The company's stock dropped over 70% following the news on May 10, 2024.
  • The investigation by Bragar Eagel & Squire raises concerns about potential violations of federal securities laws.

Full Press Release Details

NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against MacroGenics, Inc. (“MacroGenics” or the “Company”) (NASDAQ: MGNX) on behalf of MacroGenics stockholders. Our investigation concerns whether MacroGenics has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
MacroGenics revealed its clinical trial update as part of its recent earnings report, admitting that five patients had died during its TAMARACK study.
On this news, MacroGenics stock dropped over 70% on May 10, 2024.
If you purchased or otherwise acquired MacroGenics shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Frequently Asked Questions

What is Bragar Eagel & Squire investigating?

They are investigating potential claims against MacroGenics for possible violations of federal securities laws.

What recent event affected MacroGenics stock?

MacroGenics stock dropped over 70% after announcing five patient deaths in the TAMARACK study.

Who can contact Bragar Eagel & Squire for inquiries?

MacroGenics stockholders who suffered a loss or have relevant information can reach out.

Is there a cost to contact Bragar Eagel & Squire?

No, there is no cost or obligation to contact the firm for inquiries.

Where are the offices of Bragar Eagel & Squire located?

The firm has offices in New York, California, and South Carolina.

Last updated: May 15, 2024